Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 875 of 2051 entries
View as:

A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (0518-019)

Phase: N/A Priority: Normal
NCT ID: NCT00293254 Org: User:
Start: 02/28/06 End: 05/31/11 Due: 05/31/12

Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)

Phase: N/A Priority: Normal
NCT ID: NCT01697592 Org: User:
Start: 10/24/12 End: 05/08/14 Due: 05/08/15

Study of MK-1029 in Participants With Persistent Asthma That Cannot Be Controlled With Montelukast (MK-1029-015)

Phase: N/A Priority: Normal
NCT ID: NCT02720081 Org: User:
Start: 05/11/16 End: 09/06/17 Due: 09/06/18

A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101)

Phase: N/A Priority: Normal
NCT ID: NCT02028065 Org: User:
Start: 01/03/14 End: 07/01/14 Due: 07/01/15

A Laboratory-based Surveillance Study of Candida Bloodstream Infections (MK-0991-093)

Phase: N/A Priority: Normal
NCT ID: NCT01174147 Org: User:
Start: 04/30/10 End: 11/30/12 Due: 11/30/13

Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)

Phase: N/A Priority: Normal
NCT ID: NCT02453594 Org: User:
Start: 06/10/15 End: 09/18/23 Due: 09/18/24

A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)

Phase: N/A Priority: Normal
NCT ID: NCT02130466 Org: User:
Start: 05/29/14 End: 07/14/21 Due: 07/14/22

A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031)

Phase: N/A Priority: Normal
NCT ID: NCT02212730 Org: User:
Start: 12/03/14 End: 07/05/19 Due: 07/05/20

Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569)

Phase: N/A Priority: Normal
NCT ID: NCT00048724 Org: User:
Start: 06/30/02 End: 04/30/08 Due: 04/30/09

Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041)

Phase: N/A Priority: Normal
NCT ID: NCT02956629 Org: User:
Start: 11/16/16 End: 03/05/18 Due: 03/05/19

A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00411554 Org: User:
Start: 01/31/07 End: 08/31/07 Due: 08/31/08

Observational Study Assessing Chronic Hepatitis C Management in Clinical Practice in Italy (Study P05488 AM1)

Phase: N/A Priority: Normal
NCT ID: NCT00724451 Org: User:
Start: 07/31/08 End: 10/31/11 Due: 10/31/12

An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)

Phase: N/A Priority: Normal
NCT ID: NCT00092183 Org: User:
Start: 10/10/02 End: 02/11/04 Due: 02/11/05

A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002)

Phase: N/A Priority: Normal
NCT ID: NCT01390441 Org: User:
Start: 07/31/11 End: 04/30/14 Due: 04/30/15

A Study of Omarigliptin (MK-3102) in Participants With Impaired Renal Function (MK-3102-009)

Phase: N/A Priority: Normal
NCT ID: NCT01407276 Org: User:
Start: 08/08/11 End: 03/23/12 Due: 03/23/13

Safety and Efficacy Evaluation of Sugammadex in Cardiac Patients (19.4.309)(P05934)

Phase: N/A Priority: Normal
NCT ID: NCT00420680 Org: User:
Start: 11/07/05 End: 08/01/06 Due: 08/01/07

Isentress Re-examination Study (MK-0518-115)

Phase: N/A Priority: Normal
NCT ID: NCT01042808 Org: User:
Start: 05/31/11 End: 05/31/14 Due: 05/31/15

The Safety and Efficacy of an Investigational Drug in Delaying the Progression of Alzheimer's Disease

Phase: N/A Priority: Normal
NCT ID: NCT00006187 Org: User:
Start: - End: 06/30/05 Due: 06/30/06

Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension

Phase: N/A Priority: Normal
NCT ID: NCT04859582 Org: User:
Start: 11/08/18 End: 11/29/24 Due: 11/29/25

A Phase I Study of MK-4827 for Treatment of Solid Tumors (MK-4827-005)

Phase: N/A Priority: Normal
NCT ID: NCT01226901 Org: User:
Start: 11/30/10 End: 11/30/11 Due: 11/30/12

Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)

Phase: N/A Priority: Normal
NCT ID: NCT06161116 Org: User:
Start: 12/27/23 End: 03/26/28 Due: 03/26/29

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

Phase: N/A Priority: Normal
NCT ID: NCT05458297 Org: User:
Start: 07/21/22 End: 05/17/29 Due: 05/17/30

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

Phase: N/A Priority: Normal
NCT ID: NCT04728893 Org: User:
Start: 04/05/21 End: 03/19/27 Due: 03/19/28

Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)

Phase: N/A Priority: Normal
NCT ID: NCT06956235 Org: User:
Start: 06/09/25 End: 01/22/29 Due: 01/22/30

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

Phase: N/A Priority: Normal
NCT ID: NCT06351631 Org: User:
Start: 05/23/24 End: 12/04/34 Due: 12/04/35